Business Wire

Northleaf Closes on More Than US$900 Million of Investor Capital for Its Global Private Credit Strategy

Share

Northleaf Capital Partners (Northleaf) announced today that it held the final closing for Northleaf Private Credit II (NPC II) and a related separately managed account, raising more than US$900 million to invest in performing loans to global mid-market companies. Including anticipated leverage, the total investible capital amounts to approximately US$1.2 billion. Northleaf’s private credit program seeks to provide investors with diversified exposure to mid-market private credit investments and offers flexible debt financing solutions to privately held companies.

“We are pleased with the strong support from both new and existing investors,” said Stuart Waugh, Managing Partner of Northleaf. “The insights, information flows and longstanding relationships across Northleaf’s mid-market platform enable us to offer a differentiated approach to private credit investing that has resonated with investors.”

NPC II provides investors with exposure to a diversified portfolio of loans to private equity-backed and independent mid-market companies globally. The fund’s flexible investment strategy enables it to invest across the capital structure, from senior secured loans to junior debt and equity investments. To date, NPC II has invested more than 30% of its capital in loans to a diversified portfolio of private companies.

“We are excited about the robust pipeline of opportunities for NPC II,” said David Ross, Managing Director and Head of Private Credit at Northleaf. “Our established team remains highly selective in this environment, adding new borrowers that exhibit defensive and stable characteristics, and strong relative value, with the goal of delivering attractive returns and reliable income to our investors.”

Northleaf launched its private credit program in 2016 to complement its successful investment strategies in private equity and infrastructure. Northleaf has an experienced team of private credit professionals based in Chicago, London, New York and Toronto. Across its growing private credit program, Northleaf offers investors the opportunity to invest in private credit through both closed-end and open-end funds and has raised more than US$3.5 billion in capital commitments to date.

About Northleaf Capital Partners
Northleaf Capital Partners is a global private markets investment firm with more than US$17 billion in private equity, private credit and infrastructure commitments under management on behalf of public, corporate and multi-employer pension plans, endowments, foundations, financial institutions and family offices. Northleaf’s 150-person team, located in Toronto, Chicago, London, Melbourne, Menlo Park, Montreal and New York, is focused exclusively on sourcing, evaluating and managing private markets investments globally. Northleaf’s portfolio includes more than 400 active investments in 40 countries, with a focus on mid-market companies and assets. For more information on Northleaf, please visit www.northleafcapital.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Investor and media inquiries:
Nadine Cannata
Director, Communications
+1.416.477.6623
nadine.cannata@northleafcapital.com

Private Credit transaction related inquiries:
David Ross
Managing Director
+44.20.7321.5758
david.ross@northleafcapital.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Microba Delivers Landmark IBD Results & Signs Major Gastro Partner29.4.2025 08:52:00 EEST | Press release

Microba Life Sciences Limited (ASX: MAP) (“Microba”) a precision microbiome company, today announces two significant developments: the release of new clinical utility results for its MetaPanel™ gastrointestinal pathogen test, and the signing of a strategic clinical partnership with the Colonoscopy Clinic, and its wholly owned partner, Integrated Gut Health, one of Australia’s leading gastroenterology services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250428841566/en/ Transforming IBD Care: MetaPanel™ Demonstrates High Clinical Utility Two independent clinical studies led by renowned Australian gastroenterologists Associate Professor Jake Begun and Associate Professor Graham Radford-Smith have demonstrated compelling clinical utility for Microba’s MetaPanel™ in the management of patients with Inflammatory Bowel Disease (IBD), including Crohn’s disease and ulcerative colitis. The studies found that: 40% of IBD patients e

VeriSilicon Launches the Industry-Leading Automotive-Grade Intelligent Driving SoC Design Platform29.4.2025 03:00:00 EEST | Press release

VeriSilicon (688521.SH) recently announced that its automotive-grade high-performance intelligent driving system-on-chip (SoC) design platform has been verified and successfully implemented in customer projects. Leveraging VeriSilicon’s Silicon Platform as a Service (SiPaaS) business model, this platform provides robust technical support for high-performance computing applications such as autonomous driving and advanced driver assistance systems (ADAS). VeriSilicon’s chip design process has obtained ISO 26262 automotive functional safety management system certification, enabling the company to provide global customers with one-stop custom service for their automotive chips that meet functional safety requirements. Combined with its extensive portfolio of automotive-grade IPs and complete intelligent driving software platform, VeriSilicon offers end-to-end support from chip design and verification to automotive certification, including safety requirement analysis, architecture design, a

EU Authorisation Allows for Fermented Rapeseed Cake to Be Applied in Food29.4.2025 00:59:00 EEST | Press release

Most people recognise the yellow, fragrant rapeseed fields that adorn the landscape in spring. But few know that rapeseed cake was banned as food grade until today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250428371892/en/ Today is a special day for Danish FERM FOOD ApS, which has received the EU Commission's authorisation to use fermented rapeseed cake as a food ingredient (Left: Founder and CEO Jens Legarth, right: Head of Development Søren Lange). Rapeseed was banned – until today Rapeseed, also known as Canola, is primarily grown for its oil-rich seeds, which are pressed into cooking oil. While you can fill the pan with rapeseed oil, the remaining protein-rich press cake is strictly forbidden for human consumption in the EU until today. Therefore, rapeseed cake is primarily used for feed and biogas. The EU rule that prohibits rapeseed for consumption is called Novel Food and means that only foods that have been con

IFF Pharma Solutions to Showcase Portfolio at Excipient World 202529.4.2025 00:00:00 EEST | Press release

IFF (NYSE: IFF) Pharma Solutions, a global leader in polymer innovations, will showcase its sustainable solutions at Excipient World 2025. The team will feature sustainable innovations, controlled-release formulations, and nitrosamine risk mitigation solutions at booth 205 from May 13-14, Gaylord National Resort and Convention Center, National Harbor, Maryland, USA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250428283122/en/ “At IFF Pharma Solutions, we believe sustainability is not just a responsibility but an opportunity to innovate and inspire,” said Dr. Anne Adden, global strategic marketing director for sustainability and dietary supplements. “We are committed to creating solutions that not only meet the needs of today but also pave the way for a healthier, more sustainable future. Our team of problem-solvers and experts is redefining what it means to lead in sustainable healthcare.” Building on over 75 years of ind

Winka Dubbeldam Appointed Director and CEO of SCI-Arc28.4.2025 21:50:00 EEST | Press release

The Southern California Institute of Architecture (SCI-Arc) is thrilled to share that Prof. Winka Dubbeldam has been appointed as the next Director and Chief Executive Officer of SCI-Arc. A globally recognized Dutch architect, educator, and leader in design innovation, Winka will officially assume the role on September 1, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250428994100/en/ Winka Dubbeldam Winka brings more than three decades of experience to the forefront of architectural practice and education. She is a full Professor of Architecture and served as Chair at the University of Pennsylvania Stuart Weitzman School of Design for ten years (2013–2023). Previously she initiated and directed the Post-Professional Architecture program for ten years (2003–2013), providing international students with innovative design skills, cutting-edge theoretical and technological knowledge necessary for a productive and innovativ

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye